announced on Friday alongside its partner, Iterchimica, a world leader in products that enhance asphalt performance, the commencement of their UK road trial for graphene enhanced road surfaces.
According to Founder and CEO of Directa, Giulio Cesareo, the trial is considered crucial “in proving the business and use case for the next generation of graphene enhanced road surfaces.”
The trial, to take place in Curbridge, Oxfordshire, will involve laying asphalt concrete with a proprietary graphene-enhanced modifier to refurb two upper layers of a 750m long section of road.
By comparing asphalt concrete with the super modifier to a traditional asphalt surfacing, the trial will assess service life, resistance to the passage of vehicles, resistance to deformation and permanent plastic deformation.
Oxfordshire County Council has permitted the commencement of the trial, and the group’s prime contractor will be Skanska AB, a multinational construction company.
The graphene-enhanced modifier is the result of a three-year research with a patent filed in 2017 and has the potential to vastly improve the quality of road surfaces.
"This technology will allow governments to supply better quality roads for drivers and other road users, at better value for money, and in a more environmentally sustainable way,” commented Mr Cesareo.
Significantly, asphalt concrete with super modifier, once laid, can be 100% recycled, reducing the extraction of new materials from quarries and first-use bitumen.
"Working with leading companies such as Iterchemica to bring the benefits of G+ graphene enhanced products and materials to market is a key part of Directa Plus' strategy across all our key industrial verticals,” Mr Cesareo added.
Follow News & Updates from Directa Plus here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
“The potential scale and opportunity of this development is truly significant, especially given the potential synergies with our ongoing development of coal mine and mine mouth power,” commented Naheed Memon, Chief Executive of Oracle.
Kape CEO Ido Erlichman said: “In one acquisition, I believe we have positioned Kape to fast become one of the leading digital privacy service providers in the world, empowering consumers to manage their own data and digital security.”
SP Angel research note on commodities and miners, featuring: Adriatic Metals* (ADT AU) A$1.31, Mkt cap A$226.1m – Vares scoping study Arc Minerals* (ARCM LN) 2.7p, Mkt Cap £20m – Arc agrees sale of Šturec as it focuses resources on development of Cheyeza East discovery in Zambia Cora Gold* (CORA LN) 5.4p, Mkt Cap £7m – 5,000m of drilling to test lateral and dip extensions at Sanankoro Oriole Resources (ORR LN) 0.39p, Mkt cap £2.7m – Financing for Thani Stratex Resources Djibouti Pensana Metals (PM8 AU) A$0.20, Mkt cap A$30m – Pensana punchy on NdPr prices in new Feasibility Study Tri-Star Resources* (TSTR LN) 37p, Mkt Cap £35.2m – First production of commercial grade antimony metal
Matt Lofgran, Chief Executive Officer of Nostra Terra explained the company decision, commenting, “We have taken the view that because the asset is loss-making and given we are not the operator, despite the fact that we feel that we could improve operations significantly, ultimately the best resolution is for NTI to transfer its interest and have no past or future liability."
The collaboration will enable a preclinical assessment, as well as informing a clinical development strategy for Redx’s Porcupine (RXC006) and ROCK2 inhibitors which aim to enter the clinic by 2021.
“Transport refuelling is just the tip of the iceberg for demand for hydrogen from renewable sources,” said Dr Graham Cooley, CEO of ITM Power, “and this partnership will be well positioned to participate in this exciting and rapidly growing industry."